Pooled F(ab')2 fragments of three MAbs against distinct epitopes of carcinoembryonic antigen (CEA) were used for radioimmunotherapy of nude mice bearing a subcutaneous human colon carcinoma xenograft. 9-10 d after transplantation when tumor nodules were in exponential growth, 36 mice were
Introduction
After the discovery of the hybridoma technology (1) , which allows the production of MAbs directed against new tumorassociated antigens (2) (3) (4) (5) and selective antigenic determinants of known tumor markers such as carcinoembryonic antigen (CEA)' (6, 7) , there has been renewed interest in antibody-me-diated cancer therapy. Several clinical trials of cancer treatment with unlabeled antibodies involving patients with leukemia, lymphoma (8, 9) , melanoma (10) (11) (12) (13) , and colon carcinoma (14) have recently been reported. Antibodies coupled to toxins were used in a therapeutic trial of melanoma patients (15) . Polyclonal and monoclonal antibodies carrying a radioisotope of medium or high beta energy like '3'I or 9Y have been used in some clinical tumor therapy trials (16) (17) (18) (19) (20) (21) (22) . The theoretical advantage of such isotopes consists in their emission of electron particles that can penetrate and damage several cell layers around the targeted tumor cells. Thus, within a solid tumor nodule cells with low antigen expression can be lethally hit by electrons emitted from radiolabeled antibodies concentrated on adjacent tumor cells expressing more antigen.
We have selected for immunoscintigraphy of colorectal carcinomas several anti-CEA MAbs (23, 24) and have recently reported their use in a murine radioimmunotherapy model (25) as well as in a therapeutic approach in colorectal carcinoma patients (26) . The treatment was well tolerated by the patients, but the doses of radioactivity delivered to the tumors were too low to produce tumor regression.
In nude mice grafted with colon carcinoma we have obtained specific but limited tumor regressions by using a mixture of intact MAbs and their F(ab')2 fragments labeled with I'lI (25) . We describe here, in the same model, definitively more successful therapeutic results obtained by the exclusive use of F(ab')2 fragments of the same anti-CEA MAbs labeled with higher doses of 1311. Under stringent experimental conditions, including the initiation of therapy only 9-10 d after tumor transplantation and an intravenous mode of antibody administration, we have obtained complete remission of human colon carcinoma xenografts in a significant number of mice without altering their long-term survival. These results compare favorably with previous reports from the literature (27-39). A precise dosimetry, based on a time course study of the tissue distribution of "'1I in dissected animals, gives information that might be helpful for designing antibody-guided radioimmunotherapy trials in patients with disseminated colon carcinomas.
Methods
MAbs. F(ab)2 fragments from three MAbs (MAb 35, CE-25-B7 [B7] , and B17) against three independent epitopes of CEA were selected according to criteria required for therapeutic injection of patients (26, 40) , including high percentage of binding to purified CEA and no reaction with (a) the cross-reacting antigens NCA-55 and NCA-95 (41, 42) , (b) biliary glycoprotein (43), and (c) fresh human granulocytes. The '3II-labeled F(ab')2 fragments from the three MAb were shown to localize equally well into human colon carcinoma xenografts yielding high tumor to whole body ratios ranging from 35 to 50 (25) .
Preparation ofF(ab)2fragments. Antibodies or IgG from ascites of myeloma P3 X 63 (1) were precipitated with ammonium sulfate, the redissolved sediment was digested with pepsin, and F(ab')2 fragments were purified as described earlier (25, 44) . F(ab')2 fractions were shown to be 95-98% pure by SDS-PAGE.
Labeling ofF(ab)2 with 131L Batches of 1 mg of F(ab')2 fragments from single or pooled anti-CEA MAbs were labeled by the chloramine T method with 10 mCi of 30I yielding a specific activity of 8-9 MCi/Mg. Immunoreactivity of radiolabeled F(ab')2 was determined as described earlier (25) . Nude mouse tumor model and therapeutic modalities. The human colon carcinoma T380, generously provided by S. Halpern, San Diego (45), was serially transplanted subcutaneously (46) into 7-9-wk-old male "Swiss" homozygous nu/nu mice (Iffa Credo, I'Arbresle, France). Tumor T380 contains almost no necrotic areas, is moderately differentiated, and contains numerous pseudolumina that are rich in CEA (45) .
The mice were held in aseptic conditions using filter paper-topped cages and nourished with standard, vitamin-supplemented, and irradiated food. In addition, drinking water (maintained at pH 6) was supplemented with a polyvitamin (Protovit iv, 0.1 ml/300 ml water; Roche, Basel, Switzerland), and amino acid preparations (Polilevo iv, 0.05 ml/300 ml water; Piniol AG, Horw, Switzerland). Lugol iodine (5%) solution was added into drinking water (0.2 ml/300 ml) 3 d before and up to 6 wk after injection of 131I-F(ab')2.
8-10 d after subcutaneous injection of 50 mm3 of minced tumor T380 into the right flanks of the animals, I 90% of the transplants entered into exponential growth.
Therapy was started at day 9 or 10 after tumor transplantation. Nude mice were selected for evidence of tumor growth and randomly distributed into the different therapy and control groups. For each of the three series of experiments (described in Figs. 1-3 ), '31I-labeled anti-CEA MAb F(ab')2, 131I-labeled control IgG F(ab')2, and unlabeled anti-CEA MAb F(ab')2 were intravenously injected at the same day, while another control group remained untreated.
Follow-up oftreated and control mice. Three different diameters of the tumors were measured two times a week for 50 d and then once a week. Tumor volume was calculated by the formula vol = r, X r2 X r3 X 4/3 wr (r = radius). The precision of these measurements was found to be ± 10-15% when performed by different observers, by comparison of results obtained by external tumor measurements, and by direct weighing of 20 dissected tumors.
Whole body counting was performed just after injection of '3'I-F(ab')2 and every 1-2 d thereafter using an assayer (RADX Corp., Houston, TX). On the day ofinjection and every 2-3 d thereafter, mice were weighed until they recovered from the initial weight loss. At Therapy with increasing doses of'3I-labeled MAb F(ab')2.
400, 800, 1,600, and 2,800 gCi '31I-anti-CEA MAb F(ab')2
were injected as a single dose at day 9 after tumor transplantation in four groups of four to five mice. Therapy with repeated doses of400 AtCi 13]I-MAb F(ab'h.
Four doses of 400 AGCi '3I-MAb F(ab')2 were injected into nine mice at days 10, 12, 24, and 38 after tumor transplantation. Tumor regression was observed'in all nine mice, as shown in Fig. 2 From the tissue distributions of I1I-MAb F(ab')2 (Fig. 4) Morphology and CEA expression in relapsing tumors. Tumors from six mice relapsing at 55-75 d after therapy with 1,600 uCi 131I-MAb F(ab')2 administered in a single dose (experiment 1, n = 3) or in fractionated doses (experiment 2, n = 3) were analyzed histologically. In all six mice the tumor nodules showed the same differentiation degree as the original tumor. These apparently growing nodules were surrounded by areas of necrotic tumor and fibrosis. CEA expression in the numerous pseudolumina of the relapsing nodules was determined by immunocytochemistry and was as abundant as in the untreated tumors.
Histology of remaining micronodules in mice with complete remission. The small nodules remaining at the site of tumor transplantation in five successfully treated mice of experiment 1 (Fig. 1) 6 mo after therapy contained mostly fibrosis, and in three cases some rare cells of epithelial origin (encapsulated in fibrosis) with no sign of cell division. Among the 10 mice of experiment 3 (Fig. 3) who had all complete tumor remission, 2 mice were sacrificed 4 and 8 mo after therapy, and the 8 others (in good health) at 12 mo. No evidence oftumor relapse was found at autopsy. Histologic examination of the small (tumor) nodules showed fibrosis with no tumor cells in nine mice and some remaining epithelial cells (without sign of cell division) surrounded by fibrosis in the mouse that was killed at 4 mo.
Discussion
Several reports from the literature describe delayed tumor growth (27-30) and in some cases complete remission of solid tumors in nude mice by treatment with various MAbs (31) (32) (33) (34) (35) (36) (37) (38) (39) . Complete remissions, however, were often obtained by initiating antibody treatment within 24 h after tumor transplantation, when the tumor cells are not yet established and organized (31-33, 35, 37) . Thus, these tumor remissions should rather be considered as prevention of engraftment. In other experiments very large doses of radioactivity on intact antibodies were injected, which caused severe radiation toxicity and death of a high percentage of the treated animals (36, 38, 39) .
In the present experiments we started therapy 9-10 d after tumor transplantation when the human colon carcinoma xenografts were well established and in exponential growth. After injection of high doses of '31I-anti-CEA MAb F(ab')2 we could observe complete tumor regression and long-term survival of almost all animals. For instance, in the last group of 10 mice injected with 2,200 ACi 3 11-MAb F(ab)2, only 1 animal needed bone marrow transplantation, and 8 animals were observed during 12 mo in good health without tumor relapse.
The good tolerance of high doses of radioactivity appeared to be due to the exclusive use ofradiolabeled F(ab')2 fragments. In a previous study, by using a '3'I-labeled mixture of intact MAbs and F(ab')2 fragments of the same pool of three anti-CEA MAbs, we obtained either relatively short tumor regressions (25) or, when increasing the doses of '3'I, we observed, in addition to bone marrow toxicity controlled by bone marrow transplantation, severe liver toxicity at days 55-100 after injection (unpublished data).
Surprisingly, despite the demonstration of the superiority of fragments for diagnostic immunoscintigraphy both experimentally (7, 19, (50) (51) (52) (53) (54) (55) and in clinical trials (17, 19, 24) , no thorough experimental radioimmunotherapy study using radiolabeled fragments has yet been reported. The only therapeutic use of radiolabeled antibody fragments was reported by Larson et al. (17) , who used 'III-Fab fragments for the treatment of melanoma patients. Large repeated doses of '31I-Fab were well tolerated by the patients, but the radiation doses to the tumors were often too low, due to the rapid elimination of the low mol wt (50 kD) Fab fragment. Fab fragments of high affinity MAb appear to be the best carrier of isotopes for diagnostic immunoscintigraphy, especially when labeled with an isotope of relatively short physical tI/2 such as 1231 (24) . Their too rapid elimination through the kidneys, however, limits their use for therapeutic purposes, while '3II-F(ab')2 fragments with their intermediate mol wt (100 kD) are shown here to be able specifically to eliminate human colon carcinoma xenografts.
In addition, in preliminary experiments five mice with larger T380 tumors measuring 350-1,500 mm3 were treated with 2,700-3,300 uCi of 131I-MAb F(ab')2 (adapted to the tumor volume), and the tumor sizes progressively decreased and remained stable with volumes ranging from 35 to 300 mm3. All five mice were in good health 6 mo after therapy (results not shown).
The dosimetric calculations for the treatment reported in Fig. 3 indicate that in this nude mouse model an intravenous injection of 2,200 MCi of 13'I-labeled anti-CEA MAb F(ab')2 could deliver 8,335 rad to the subcutaneous tumors with only 617 rad absorbed by the liver. This tumor to liver radiation ratio of 13.5 is very encouraging, and our more recent results, presented in Table I , indicate that tumor to normal tissue radiation ratios could be further increased for all organs by injections of lower amounts of F(ab')2 fragments.
The results obtained with 1,600 ,uCi injected in fractionated doses (4 X 400 ,Ci, four complete remissions out of nine animals) as compared with the mice injected with a single dose of 1,600 ,uCi (one complete remission out of five animals) indicate a slight advantage in favor of the fractionated doses. This advantage is not statistically significant (P < 0.4), but we interpret the results to mean that repeated injections of small doses are at least as effective as the injection of a single high dose.
The complete remission of colon carcinoma xenografts in 100% of the animals required the injection of high doses of '31I-F(ab')2 (2, 200 uCi) . The requirement of such high doses is essentially due to the very short initial whole body t1/2 of F(ab')2 (-12 h) in the mouse and as a consequence also the relatively short t1/2 (-24 h) in the tumor (Fig. 4) . In patients, however, the whole body and the tumor t1/2 of F(ab')2 can be definitively longer, ranging from 24 to 48 h depending on the amount of fragments injected (unpublished observation). Thus, the amount of injected "3 I-F(ab')2 fragments required to sterilize a tumor in the mouse cannot be directly extrapolated to the patients' situation.
In patients, however, we may encounter several additional problems. First, the bone marrow tolerance to radiation is lower in humans than in mice and the longer whole body t1/2 of F(ab')2 in patients may lead to more bone marrow toxicity. Second, the fact that CEA is present in normal tissues (such as normal gut) (56) may increase binding of antibody, and consequently radiation to these organs. Furthermore, the presence of CEA in circulation may provoke the formation of immune complexes that might accumulate in the reticulo-endothelium. In our limited clinical experience in the treatment of liver metastases from colon carcinoma by injection of large doses of '3'I (100-300 mCi) linked to anti-CEA MAb (intact and F(ab')2 fragments) we have not yet obtained significant tumor remission (Delaloye et al., manuscript in preparation, and ref- erence 26) . The only limitation, however, has been bone marrow toxicity, a problem that might be overcome by using autologous bone marrow transplantation.
Without underestimating the obvious differences between clinical and experimental radioimmunotherapy, we considered it important in the present study to select experimental conditions as close as possible to the clinical situation, including a systemic route of antibody administration, the treatment of well-established human carcinoma xenografts, and the use of F(ab')2 fragments from anti-CEA MAbs which had been shown to be well tolerated in patients (26) .
We have demonstrated that complete ablation of human colon carcinoma xenografts in nude mice can be obtained by a single or by repeated intravenous injections of '31I-anti-CEA MAb F(ab')2. Interestingly, the different treatments described here were well tolerated by the animals, since out of 19 
